Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1993 Sep;92(3):1587–1591. doi: 10.1172/JCI116740

Interaction of nitric oxide and cyclic guanosine 3',5'-monophosphate in erythropoietin production.

T Ohigashi 1, J Brookins 1, J W Fisher 1
PMCID: PMC288308  PMID: 8397229

Abstract

The present study was designed to investigate whether in vivo and in vitro erythropoietin (EPO) production is modulated by nitric oxide (NO) and cyclic guanosine 3',5'-monophosphate (cGMP). Serum levels of EPO in ex-hypoxic polycythemic mice were significantly increased after injections of 200 micrograms/kg sodium nitroprusside for 4 d. One injection of NG-nitro-L-arginine methyl ester (L-NAME) produced a significant dose-related decrease in serum levels of EPO in ex-hypoxic polycythemic mice in response to hypoxia. When EPO producing Hep3B cells were incubated in 1% O2 for 30 min, cGMP levels in the Hep3B cells were significantly elevated, compared with cells incubated in 20% O2. The elevation of cGMP by hypoxia was inhibited by L-NAME (100 microM). Sodium nitroprusside (10 and 100 microM) and NO (2 microM) also significantly increased cGMP levels in Hep3B cells. L-NAME, LY 83583 (6-Anilino-5,8-quinolinedione, a soluble guanylate cyclase inhibitor), and Rp-8-Bromo-cGMPS (Rp-8-Bromo-guanosine 3',5'-cyclic monophosphothioate, a cGMP-dependent protein kinase inhibitor) significantly inhibited the hypoxia-induced increase in medium levels of EPO in Hep3B cells. 8-Bromo-cGMPS produced a dose-dependent decrease in EPO messenger RNA levels in Hep3B cells in response to hypoxia. 8-Bromo-cGMP (10(-3) M) produced significant increases in medium levels of EPO in Hep3B cell cultures incubated under normoxic conditions, which was enhanced by the phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine (0.2 mM). These results suggest that NO and cGMP may interact in modulating hypoxic stimulation of EPO production.

Full text

PDF
1587

Images in this article

1588Image
on p.1588
1588Image
on p.1588
1588Image
on p.1588
1589Image
on p.1589

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bates J. N., Baker M. T., Guerra R., Jr, Harrison D. G. Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem Pharmacol. 1991 Dec 11;42 (Suppl):S157–S165. doi: 10.1016/0006-2952(91)90406-u. [DOI] [PubMed] [Google Scholar]
  2. Brezis M., Heyman S. N., Dinour D., Epstein F. H., Rosen S. Role of nitric oxide in renal medullary oxygenation. Studies in isolated and intact rat kidneys. J Clin Invest. 1991 Aug;88(2):390–395. doi: 10.1172/JCI115316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brüne B., Schmidt K. U., Ullrich V. Activation of soluble guanylate cyclase by carbon monoxide and inhibition by superoxide anion. Eur J Biochem. 1990 Sep 24;192(3):683–688. doi: 10.1111/j.1432-1033.1990.tb19276.x. [DOI] [PubMed] [Google Scholar]
  4. Butt E., Nolte C., Schulz S., Beltman J., Beavo J. A., Jastorff B., Walter U. Analysis of the functional role of cGMP-dependent protein kinase in intact human platelets using a specific activator 8-para-chlorophenylthio-cGMP. Biochem Pharmacol. 1992 Jun 23;43(12):2591–2600. doi: 10.1016/0006-2952(92)90148-c. [DOI] [PubMed] [Google Scholar]
  5. Butt E., van Bemmelen M., Fischer L., Walter U., Jastorff B. Inhibition of cGMP-dependent protein kinase by (Rp)-guanosine 3',5'-monophosphorothioates. FEBS Lett. 1990 Apr 9;263(1):47–50. doi: 10.1016/0014-5793(90)80702-k. [DOI] [PubMed] [Google Scholar]
  6. Carmichael J., DeGraff W. G., Gazdar A. F., Minna J. D., Mitchell J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987 Feb 15;47(4):936–942. [PubMed] [Google Scholar]
  7. Curran R. D., Billiar T. R., Stuehr D. J., Hofmann K., Simmons R. L. Hepatocytes produce nitrogen oxides from L-arginine in response to inflammatory products of Kupffer cells. J Exp Med. 1989 Nov 1;170(5):1769–1774. doi: 10.1084/jem.170.5.1769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fisher J. W. Pharmacologic modulation of erythropoietin production. Annu Rev Pharmacol Toxicol. 1988;28:101–122. doi: 10.1146/annurev.pa.28.040188.000533. [DOI] [PubMed] [Google Scholar]
  9. Goldberg M. A., Dunning S. P., Bunn H. F. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science. 1988 Dec 9;242(4884):1412–1415. doi: 10.1126/science.2849206. [DOI] [PubMed] [Google Scholar]
  10. Goldberg M. A., Gaut C. C., Bunn H. F. Erythropoietin mRNA levels are governed by both the rate of gene transcription and posttranscriptional events. Blood. 1991 Jan 15;77(2):271–277. [PubMed] [Google Scholar]
  11. Goldberg M. A., Glass G. A., Cunningham J. M., Bunn H. F. The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci U S A. 1987 Nov;84(22):7972–7976. doi: 10.1073/pnas.84.22.7972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gray G. A., Schott C., Julou-Schaeffer G., Fleming I., Parratt J. R., Stoclet J. C. The effect of inhibitors of the L-arginine/nitric oxide pathway on endotoxin-induced loss of vascular responsiveness in anaesthetized rats. Br J Pharmacol. 1991 May;103(1):1218–1224. doi: 10.1111/j.1476-5381.1991.tb12327.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hidaka H., Inagaki M., Kawamoto S., Sasaki Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry. 1984 Oct 9;23(21):5036–5041. doi: 10.1021/bi00316a032. [DOI] [PubMed] [Google Scholar]
  14. Ignarro L. J. Endothelium-derived nitric oxide: actions and properties. FASEB J. 1989 Jan;3(1):31–36. doi: 10.1096/fasebj.3.1.2642868. [DOI] [PubMed] [Google Scholar]
  15. Klatt P., Schmidt K., Mayer B. Brain nitric oxide synthase is a haemoprotein. Biochem J. 1992 Nov 15;288(Pt 1):15–17. doi: 10.1042/bj2880015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Malgor L. A., Fisher J. W. Antagonism of angiotensin by hydralazine on renal blood flow and erythropoietin production. Am J Physiol. 1969 Mar;216(3):563–566. doi: 10.1152/ajplegacy.1969.216.3.563. [DOI] [PubMed] [Google Scholar]
  17. Mason-Garcia M., Beckman B. S., Brookins J. W., Powell J. S., Lanham W., Blaisdell S., Keay L., Li S. C., Fisher J. W. Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin. Kidney Int. 1990 Nov;38(5):969–975. doi: 10.1038/ki.1990.299. [DOI] [PubMed] [Google Scholar]
  18. Menon N. K., Wolf A., Zehetgruber M., Bing R. J. An improved chemiluminescence assay suggests non nitric oxide-mediated action of lysophosphatidylcholine and acetylcholine. Proc Soc Exp Biol Med. 1989 Jul;191(3):316–319. doi: 10.3181/00379727-217-rc2. [DOI] [PubMed] [Google Scholar]
  19. Moncada S., Palmer R. M., Higgs E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 Jun;43(2):109–142. [PubMed] [Google Scholar]
  20. Mundel P., Bachmann S., Bader M., Fischer A., Kummer W., Mayer B., Kriz W. Expression of nitric oxide synthase in kidney macula densa cells. Kidney Int. 1992 Oct;42(4):1017–1019. doi: 10.1038/ki.1992.382. [DOI] [PubMed] [Google Scholar]
  21. Mülsch A., Lückhoff A., Pohl U., Busse R., Bassenge E. LY 83583 (6-anilino-5,8-quinolinedione) blocks nitrovasodilator-induced cyclic GMP increases and inhibition of platelet activation. Naunyn Schmiedebergs Arch Pharmacol. 1989 Jul;340(1):119–125. doi: 10.1007/BF00169217. [DOI] [PubMed] [Google Scholar]
  22. Nakashima J., Brookins J., Fisher J. W. Characterization of erythropoietin production in a hepatocellular carcinoma cell line. J Lab Clin Med. 1992 Mar;119(3):306–314. [PubMed] [Google Scholar]
  23. Nelson P. K., Brookins J., Fisher J. W. Erythropoietic effects of prostacyclin (PGI2) and its metabolite 6-keto-prostaglandin (PG)E1. J Pharmacol Exp Ther. 1983 Aug;226(2):493–499. [PubMed] [Google Scholar]
  24. Pohl U., Busse R. Hypoxia stimulates release of endothelium-derived relaxant factor. Am J Physiol. 1989 Jun;256(6 Pt 2):H1595–H1600. doi: 10.1152/ajpheart.1989.256.6.H1595. [DOI] [PubMed] [Google Scholar]
  25. Radermacher J., Klanke B., Schurek H. J., Stolte H. F., Frölich J. C. Importance of NO/EDRF for glomerular and tubular function: studies in the isolated perfused rat kidney. Kidney Int. 1992 Jun;41(6):1549–1559. doi: 10.1038/ki.1992.225. [DOI] [PubMed] [Google Scholar]
  26. Ueno M., Rondon I., Beckman B., Brookins J., Nakashima J., Cole F. E., Fisher J. W. Increased secretion of erythropoietin in human renal carcinoma cells in response to atrial natriuretic factor. Am J Physiol. 1990 Sep;259(3 Pt 1):C427–C431. doi: 10.1152/ajpcell.1990.259.3.C427. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES